

Headache Pathophysiology for Clinicians

Migraine and Trigeminal Autonomic Cephalalgias: Pathophysiology, Diagnosis and Management

XXVI World Congress of Neurology

15th October 2023

Peter J. Goadsby
King's College London, UK
University of California, Los Angeles, USA

Disclosure of Financial Relationships

ICJME + ACCME format: 2021-2023

Dr Goadsby reports

- Personal fees from

- Aeon Biopharma (prabotulinumtoxinA)
- AbbVie (*aka*, Allergan: onabotulinum toxin type A/ ubrogepant/atogepant)
- Amgen (erenumab)
- CoolTech LLC
- Dr Reddys Laboratories
- Eli-Lilly (galcanezumab/lasmiditan)
- Epalex
- Lundbeck (Alder Biopharmaceuticals/eptinezumab)
- Novartis (erenumab)
- Praxis
- Pfizer (Biohaven/rimegepant/zavegepant)
- Sanofi
- Satsuma (dihydroergotamine)
- Shiratronics
- Teva Pharmaceuticals (fremanezumab)
- Tremeau

- Grants to Institution

- Celgene

- Other

- Consulting: Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector metric
- Educational materials: WebMD, Omnia Education, CME Outfitters
- Publishing: Up-to-Date, Massachusetts Medical Society, Oxford University Press, WoltersKluwer

- Patents

- *Magnetic stimulation for headache pending; licensed to eNeura without fee

Learning Objectives

- To outline some neurobiological explanations for the premonitory symptoms of migraine
 - To describe the anatomy and physiology of pain phase of the migraine attack
 - To correlate the neurobiology underpinning migraine with its clinical presentation
- **Key message**: Advances in our understanding of migraine pathophysiology can be used in daily clinical practice.